Wave Life Sciences announces continued momentum in GSK collaboration

Wave Life Sciences (WVE) provided an update on its best-in-class small interfering RNA and RNA editing platform capabilities. As part of Wave’s ongoing collaboration with GSK (GSK), GSK has selected its first two programs to advance to development candidates following achievement of target validation. These programs utilize Wave’s next generation GalNAc-siRNA format and are in hepatology. GSK will provide an aggregate initiation payment of $12 million to Wave for these two oligonucleotide programs. Under the agreement, GSK can advance up to eight programs leveraging Wave’s PRISM platform and multiple RNA-targeting modalities with target validation work ongoing across multiple therapy areas.